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EDITORIAL
ECG monitoring after acute ischemic stroke
Does patient selection matter?





To prevent stroke recurrence, we treat patients based on the presumed underlying etiology;
however, in clinical practice, the underlying mechanism remains undetermined in up to 30% of
patients.1 Atrial fibrillation (AF), a known and frequent culprit for cardioembolic stroke, can be
transient and not present at the time of evaluation following a stroke. Treatment differs for
patients who have strokes caused by AF because of the high risk of recurrent stroke with AF and
the high degree of effectiveness of oral anticoagulants to reduce cardioembolic stroke risk.
Several guidelines recommend aminimumof 24 to 48 hours of Holter monitoring in all patients
with stroke to identify AF as the underlying source of stroke.2 Previous studies found that
Holter ECGmonitoring (24–72 hours) detects paroxysmal AF in approximately 5% of patients
with stroke, and longer duration ECG monitoring detects AF in an additional 5% to 30% of
patients depending on the type and duration of monitoring.2–4
Despite this increasing evidence in support of the effectiveness of prolonged ECG monitoring
for the improved detection of AF, the implementation rate in routine clinical practice remains
low. For example, among 17,398 consecutive patients with stroke from the Ontario Stroke
Registry (2003–2013), only 30.6% of patients received at least 24 hours of Holter monitoring
30 days after stroke and less than 1% of patients received monitoring beyond 48 hours.2 Results
from surveys collected worldwide show very similar results: less than 20% of patients with stroke
receive more than 48 hours of Holter ECG.5 Reasons for the lack of implementation of cardiac
rhythm monitoring include logistical challenges, patient adherence, and costs, among others.
Many questions remain. Which patient will likely benefit from long-term ECG monitoring?
Should all cryptogenic stroke patients with presumed embolic source of stroke undergo long-
term ECG monitoring? Would an alternative approach in which monitoring is allocated to
patients at high risk of AF be more cost-effective? Moreover, what should we do about patients
with other presumed causes of stroke? For example, should a patient with a clear large vessel
stroke (e.g., ipsilateral high-grade carotid stenosis), or a lacunar stroke, also be monitored for
longer than 24 hours, since small or large vessel atherosclerosis does not protect them from AF
and subsequent strokes due to AF?
In this issue ofNeurology®, Uphaus et al.6 derived and validated a simple prediction score for AF
in ischemic stroke patients without a history of AF. They used data from 3 different studies
(total n = 1,556), consisting of stroke (78%) or TIA (22%) patients with at least 72 hours of
ECGHolter monitoring. They identified 77 cases of AF (5%). They defined AF as >30 seconds
of arrhythmia within 72 hours of the stroke. They entered and retained candidate variables
using logistic regression with backward selection. The authors derived a score they named AS5F
(Age: 0.76 points/year, Stroke Severity NIHSS ≤5 = 9 points, NIHSS >5 = 21 points; to Find
AF). The authors report a high-risk group of patients (a score above 67.5), which corresponded
to a 5.2% risk and a number needed to screen below 20 to observe one case of AF within 72
hours.
The proposed AS5F score has several strengths, including its simplicity and reported ability to
discriminate individuals at high risk of developing AF also in patients without a presumed
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cardioembolic source (e.g., small vessel strokes). We com-
mend the authors for bringing a systematic statistical ap-
proach to addressing a problem of clinical relevance.
Several limitations warrant mentioning. First, this was
a small sample. The derivation set included only 44 cases of
AF and the validation set only 33 cases. The small sample
size can bias the weights used in the score and lead to
inaccurate probability estimates. Second, many other val-
idated predictors of AF exist, which were not retained in
the current model (probably because of the small sample
size and limited power). These predictors include race,
routinely ascertained clinical risk factors,7 as well as other
measures such as P wave terminal force in V1 on the initial
routine 12-lead ECG8 or natriuretic peptides9 measured
on admission with the first blood draw. These measures
may substantially increase the predictive accuracy of the
score and should therefore be assessed in future studies.
Third, with the increasing availability of technology to
monitor cardiac rhythms, questions are likely to be cen-
tered on appropriate allocation of monitors for long-term
AF detection, rather than short-term detection within 72
hours.4,10
In the context of the recently published negative results of the
Navigate ESUS (Embolic Stroke of Undetermined Source)
trial,11 there is much we still do not understand about the
interplay between the presumed mechanism of stroke and AF
risk. Future studies are warranted to determine whether an
approach of identifying high AF-risk patient groups for un-
derlying AF or even atrial cardiopathy,12 to guide the utili-
zation of cardiac rhythm monitoring or anticoagulation, is
effective.
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